OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
For joining details please see the Society’s FB events page: fb.me/e/15v36zbce
The Domingos laboratory researches neuroimmune mechanisms underlying obesity. They discovered neuro-adipose junctions, between white adipocytes and sympathetic neurons, that are necessary and sufficient for fat mass reduction via norepinephrine (NE) signalling. Moreover, they discovered Sympathetic neuron-
Associated Macrophages (SAMs) that import and metabolize NE. Abrogation of SAM function promotes long-term amelioration of obesity independently of food intake. These findings inspired the development of a new class of anti-obesity compounds named sympathofacilitators, which do not enter the brain, nor have the typical cardiovascular side effects of centrally acting sympathomimetic drugs. Sympathofacilitator drugs act as an energy sink by coupling thermogenesis to active heat dissipation.
Ana Domingos is a member of the advisory board of Cell Metabolism and is a member of the board of reviewing editors at eLife. Her lab has been funded by HHMI, Wellcome Trust, ERC, HFSP, EMBO among other.
